Breast tumor kinase (Brk) is a member of the Frk family of nonreceptor tyrosine kinases that is overexpressed in a high percentage of human breast tumors. The downstream substrates and effectors of Brk remain largely unidentified. In this study, we carried out immunoprecipitation and mass spectrometry experiments to identify new Brk binding partners. One interacting protein was insulin receptor substrate 4 (IRS-4), a member of the IRS family. We confirmed that Brk associates with IRS-4 in resting and insulin-like growth factor 1 (IGF-1)-stimulated HEK 293 cells. The SH3 and SH2 domains of Brk are both involved in the association. The tyrosine phosphorylation of Brk increases after stimulation with IGF-1, and in MCF-7 breast cancer cells we show that the presence of IRS-4 enhances this effect. Finally, we demonstrate that endogenous Brk and IRS-4 interact in A431 human epidermoid carcinoma cells.
Breast tumor kinase (Brk) is a member of the Frk family of nonreceptor tyrosine kinases that is overexpressed in a high percentage of human breast tumors. The downstream substrates and effectors of Brk remain largely unidentified. In this study, we carried out immunoprecipitation and mass spectrometry experiments to identify new Brk binding partners. One interacting protein was insulin receptor substrate 4 (IRS-4), a member of the IRS family. We confirmed that Brk associates with IRS-4 in resting and insulin-like growth factor 1 (IGF-1)-stimulated HEK 293 cells. The SH3 and SH2 domains of Brk are both involved in the association. The tyrosine phosphorylation of Brk increases after stimulation with IGF-1, and in MCF-7 breast cancer cells we show that the presence of IRS-4 enhances this effect. Finally, we demonstrate that endogenous Brk and IRS-4 interact in A431 human epidermoid carcinoma cells. Breast tumor kinase (Brk) is a nonreceptor tyrosine kinase that was originally cloned from a human metastatic breast tumor (Mitchell et al., 1994) . It has a rather limited normal tissue expression; Brk is detected in terminally differentiating epithelial cells in the gastrointestinal tract, and in luminal epithelial cells of the prostate (Vasioukhin et al., 1995; Llor et al., 1999) . On the other hand, Brk expression is detected in a high percentage of human breast tumors, although it is absent from normal mammary tissue (Barker et al., 1997; Harvey and Crompton, 2004 ).
Brk appears to promote the proliferation of breast carcinoma cells. When overexpressed in HB4a human mammary luminal epithelial cells (which normally lack Brk), Brk sensitized the cells to the mitogenic effects of EGF (Kamalati et al., 1996) . Further study showed that Brk enhanced the EGF-induced ErbB3 phosphorylation and its interaction with PI3K, resulting in enhanced Akt activation (Kamalati et al., 2000) . Brk overexpression also supported anchorage-independent growth of NIH3T3 fibroblasts (Kamalati et al., 1996) . Suppression of Brk expression in T47D breast carcinoma cells (by RNA interference) reduced cell growth (Harvey and Crompton, 2003) . Collectively, these results suggest that Brk plays an important role in promoting cell proliferation and survival.
Brk contains SH3, SH2, and kinase catalytic domains, in an arrangement similar to that of Src-family kinases. In contrast to Src kinases, Brk has a short unique domain and lacks an N-terminal myristoylation site. In vitro kinase studies demonstrated that Brk is autoinhibited by intramolecular interactions involving the SH3 and SH2 domains (Qiu and Miller, 2002) . The SH3 and SH2 domains are also involved in substrate recognition (Qiu and Miller, 2004) . Four Brk interacting proteins have been identified: the nuclear RNA-binding protein Sam68, a novel adaptor protein designated BKS, protein kinase B/Akt, and GAP-A.p65, a GTPaseactivating protein-associated protein (Vasioukhin and Tyner, 1997; Derry et al., 2000; Mitchell et al., 2000; Zhang et al., 2005) . Brk phosphorylates Sam68, Akt, and BKS. The phosphorylation of Sam68 led to decreased RNA-binding capability and decreased Revhomologue function (Derry et al., 2000) . Relatively little is known about the cellular mechanisms of Brk regulation. In order to understand the cellular roles of Brk, it is necessary to identify additional binding partners and downstream effectors.
In this study, we undertook a proteomic approach to identify novel Brk binding partners. We report on a new Brk interacting protein, insulin receptor substrate 4 (IRS-4). IRS-4 is the most recently identified member of the IRS family which contains IRS-1, IRS-2, IRS-3, and IRS-4. IRS proteins mediate a variety of biological effects downstream of the insulin and insulin-like growth factor 1 (IGF-1) receptors, including cell proliferation, growth, survival, and differentiation. Upon receptor activation, IRS proteins become phosphorylated and provide docking sites for SH2 domain containing proteins such as PI3K and Grb2 (Giovannone et al., 2000; Sesti, 2000; Sesti et al., 2001) . The various IRS proteins may play redundant or complementary roles in IR-and IGF1R-mediated effects. IRS-4 was cloned from HEK 293 cells, and it is the major tyrosine-phosphorylated protein in these cells after treatment with insulin-or IGF-1 (Fantin et al., 1998) . It has a similar modular structure as other IRS proteins, with PH and PTB domains and a large carboxy-terminal region containing several phosphotyrosine motifs for SH2-domain binding (Lavan et al., 1997; Fantin et al., 1998) . As is true for IRS-1 and IRS-2, IRS-4 transduces the mitogenic effects of IGF-1. IRS-4 overexpression in 32D or 3T3 cells enhanced insulin or IGF-1-induced cell proliferation (Fantin et al., 1999; Qu et al., 1999) . Upon IGF-1 stimulation, IRS-4 is rapidly phosphorylated and binds to PI3K and Grb2, which then leads to increased Akt and MAPK signaling. IRS-4 was also found to interact with Crk-II and Crk-L upon IGFR activation (Koval et al., 1998) . In contrast to IRS-1/IRS-2 which are relatively ubiquitously expressed, IRS-4 mRNA is detected in restricted human tissues and cell lines. IRS-4 mRNA is found in pituitary, thyroid, ovary, prostate, fibroblasts, and several carcinoma cell lines (Sesti et al., 2001) . Approximately half of the IRS-4 in 293 cells is found in cellular membranes, with a high concentration at the plasma membrane (Fantin et al., 1998) . In contrast, most of the IRS-1 in 3T3-L1 adipocytes is found in low-density microsomes, with only a small fraction at the plasma membrane (Sun et al., 1997) . Thus, the various IRS proteins may have specific functions as a result of different tissue expression, different subcellular localization, and specific protein interactions.
Here, we initially identified the interaction between IRS-4 and Brk by immunoprecipitation and mass spectrometry. We confirmed that Brk associates with IRS-4 both in quiescent and IGF-1-stimulated HEK 293 cells. The presence of IRS-4 enhances Brk phosphorylation in response to IGF-1. We also demonstrate that endogenous Brk and IRS-4 interact in two cancer cell lines.
Results
To identify new interacting partners for Brk, we engineered the Brk coding sequence into a 3 Â FLAGtagged mammalian expression vector and transiently overexpressed Brk in HEK 293 cells. We immunoprecipitated Brk 48 h after transfection with anti-FLAG antibody, separated the precipitated proteins by SDS-PAGE, and visualized the proteins by Coomassie staining. As a control, we carried out an anti-FLAG immunoprecipitation reaction using nontransfected HEK 293 cells. The gel lanes containing the immunoprecipitated proteins from both Brk ( þ ) and Brk (À) cells were divided into 10 sections each and excised from the gel for identification by mass spectrometry. This experiment was carried out three times and the proteins identified in the three experiments were compared with proteins identified in the three control samples. We identified IRS-4 as being unique to the Brk-transfected cells in all three experiments, and as the major Brkinteracting protein in two of the experiments. The IRS-4 peptides identified by mass spectrometry are presented in Table 1 .
To confirm the interaction between Brk and IRS-4, we transiently transfected 293 cells with untagged Brk, immunoprecipitated with anti-Brk antibody (or with rabbit IgG as control), then immunoblotted with anti-IRS-4 antibody. We detected endogenous IRS-4 specifically in Brk immunoprecipitations from Brkoverexpressing cells (Figure 1a) . We tested whether cell Figure 1c) . The results showed a modest decrease in binding to IRS-4 for BrkDSH3, while the Ndel and DSH2 constructs bound approximately equal amounts of IRS-4 as wild-type Brk. These data suggested that the Brk SH3 domain was a binding site for IRS-4. There was detectable IRS-4 interacting with BrkDSH3, however, suggesting that other domains of Brk might also be involved in IRS-4 binding. To test explicitly for binding between IRS-4 and the SH3 and SH2 domains of Brk, we made GST fusion proteins containing these domains. We immobilized these fusion proteins on glutathione-agarose and incubated them (or GST control beads) with lysates from unstimulated or IGF-1-stimulated 293 cells. IRS-4 from unstimulated cells bound to both SH3 and SH2 domains, with higher binding to the SH3 domain ( Figure 2a ). After IGF-1 stimulation, we detected a twofold increase in the amount of IRS-4 binding to the Brk SH2 domain, while the SH3 domain binding did not change. The increase in binding to the Brk SH2 domain mirrored the increase in Brk/IRS-4 interaction seen in Figure 1b , suggesting that Brk SH2 domain accounts for the increased IRS-4/Brk interaction upon IGF-1 stimulation. On the other hand, in unstimulated cells the DSH2 form of Brk still bound IRS-4, suggesting that the association in the basal state depends on the SH3 domain, and perhaps other domains as well.
Previous studies in IRS-deficient cells have suggested that at least some of the roles of IRS-4 are redundant with IRS-1 and IRS-2 (Escribano et al., 2003; Lingohr et al., 2003) . To determine if the interaction between Brk and IRS-4 is specific, we compared the ability of IRS-1 and IRS-4 to bind to immobilized Brk domains. The source of IRS-1 was lysates from CHO cells, as these cells have abundant endogenous IRS-1 expression. In each case, we compared the amount of bound IRS protein to the amount present in a sample of total cell lysate. In contrast to IRS-4, for which we detected significant binding to Brk SH3 and SH2 domains, only weak binding was observed between IRS-1 and the Brk SH3 domain (Figure 2b ). There was no detectable binding to the Brk SH2 domain. Furthermore, stimulation of the cells with IGF-1 did not change the binding of IRS-1 to the immobilized Brk domains ( Figure 2b ). As expected, IRS-1 was strongly tyrosine phospho- Interaction between Brk and IRS-4 H Qiu et al rylated upon IGF-1 stimulation in this experiment (data not shown). This suggests that there is a degree of selectivity among IRS proteins for binding to Brk, with IRS-4 interacting more strongly than the related IRS-1 protein.
In the next series of experiments, we tested whether overexpression of one of the two components in the complex (Brk and IRS-4) increased the activation of the other component. First, we examined IRS-4 phosphorylation upon IGF-1 stimulation in the absence and presence of Brk. IRS-4 was precipitated from untransfected or Brk-transfected 293 cells and immunoblotted with antiphosphotyrosine antibody. Consistent with previous reports, IGF-1 treatment led to significantly enhanced IRS-4 tyrosine phosphorylation (Figure 3a) . The presence of Brk did not appear to affect the time course or the extent of IRS-4 phosphorylation. We also examined the association between IRS-4 and the downstream SH2-containing proteins PI3K and Grb2. We detected a basal interaction between IRS-4 and PI3K, and increased association upon IGF-1 stimulation. The interaction between IRS-4 and Grb2 was dramatically induced upon IGF-1 stimulation (Figure 3a) . Brk overexpression caused only minor effects on the association between IRS-4 and PI3K or IRS-4 and Grb2. We obtained similar results for IRS-4 phosphorylation and complex formation using different concentrations of IGF-1 (data not shown). We repeated these experiments using kinase-dead (K219M) and kinaseactive (Y447F) forms of Brk, and examined the IRS-4 phosphorylation and complex formation. Expression of the Brk mutants did not significantly affect IRS-4 signaling, and there was no difference between wildtype Brk and kinase-dead Brk (Figure 3b ).
Next, we tested the possibility that IRS-4 regulates Brk activity. There is abundant endogenous IRS-4 expression in 293 cells. To test for the influence of IRS-4 on Brk, we used MCF-7 breast cancer cells, which have undetectable IRS-4 protein and low levels of Brk expression. We expressed IRS-4 alone, or IRS-4 together with Brk, in MCF-7 cells and stimulated the cells with IGF-1 for 10 min. As was seen in 293 cells, the overexpressed IRS-4 became tyrosine phosphorylated in response to IGF-1 stimulation. There was also increased binding between IRS-4 and PI3K and Grb2, indicating that the overexpressed IRS-4 was functional in these cells (Figure 4a ). To examine Brk activation, we immunoprecipitated Brk from MCF-7 cells and probed with anti-phosphotyrosine antibody (Figure 4b ). In cells cotransfected with IRS-4, there was a large increase in (Figure 4b ). Treatment with IGF-1 also led to an increase in the amount of IRS-4 that co-precipitated with Brk (Figure 4b ). To confirm that the increase in Brk phosphorylation was accompanied by Brk activation, we carried out kinase assays of Brk immunoprecipitated from MCF-7 cells ( Figure  5 ). Immunoprecipitated Brk was incubated with [g-32 P]ATP, followed by SDS-PAGE and autoradiography. Treatment of Brk/IRS-4-expressing cells with IGF-1 led to an increase in the kinase activity of Brk ( Figure 5 ). We observed activation of Brk in 293 cells as well, although in that case the degree of activation was smaller, due to heavy Brk phosphorylation in the basal state (data not shown). Overall, these data suggested that Brk was phosphorylated in response to IGF-1 stimulation, and that IRS-4 enhances this response. This is the first report of Brk activation in response to a growth factor other than EGF.
The experiments presented above were carried out either with endogenous IRS-4 and overexpressed Brk (in 293 cells) or with both components overexpressed (in MCF-7 cells). We next wished to test whether the two proteins interact in cells where both are endogenously expressed. Brk protein expression has previously been detected in many breast cancer cell lines (Barker et al., 1997) . IRS-4 mRNA has been detected in several epidermoid carcinoma cell lines, as well as in normal ovary and prostate (Sesti et al., 2001) . We carried out Western blotting experiments for IRS-4 and Brk in seven different human cancer cell lines. The results showed that almost all the cells have detectable Brk protein expression (Figure 6a ). In the case of IRS-4, we detected a 160 kDa band at the expected position from The mass spectrometry approach taken here could potentially detect indirect or long-range interactions, in addition to direct protein-protein interactions. In the case of IRS-4, we showed binding between IRS-4 in cell lysates and purified, immobilized SH3 and SH2 domains from Brk, making this possibility less likely. Our immunoprecipitation and in vitro GST pulldown assays indicate that both the SH3 and SH2 domains of Brk are involved in IRS-4 binding (Figures 1 and 2) . These results are reminiscent of previous reports on the interaction between IRS-4 and CrkII and CrkL. Both CrkL SH3 and SH2 are required for maximum binding between IRS-4 and CrkL (Koval et al., 1998) . For CrkII, the association was between the SH2 domain of CrkII and four tyrosine phosphorylation sites in IRS-4 (Karas et al., 2001) . We found 15 proline-rich sequences in IRS-4 to be potential SH3 domain-binding motifs. Among them, four sequences are typical type I SH3 ligands with the sequence motif PXXPXR. IRS-4 was found to be rapidly phosphorylated upon IGF-1 stimulation (Figure 3) . IRS-4 contains 12 potential tyrosine phosphorylation sites that fit the consensus for binding the SH2 domains from the p85 subunit of PI3K, Grb2, and PLCg (Lavan et al., 1997) . Although IRS-4 does not contain the ideal Brk SH2 domain-binding sequences (pYEEY, pYDEY, pYEDY, and pYDDY) (Derry et al., 2000) , related IRS-4 phosphotyrosine motifs such as pYRAY, pYNND, pYDAE, and pYVVD may mediate binding to the Brk SH2 domain. Further work will be needed to map the precise sequences for interaction.
The GST pulldown experiments in Figure 2 showed that IRS-1 did not bind to the Brk SH3 or SH2 domains as tightly as IRS-4. Co-immunoprecipitation experiments using HEK 293, HeLa, and MCF-7 cells with transfected Brk also failed to detect Brk/IRS-1 interactions either with or without IGF-1 stimulation (data not Interaction between Brk and IRS-4 H Qiu et al shown). Although IRS-4 has a very similar modular structure to other IRS members, it displays only 27 and 29% sequence identity with IRS-1 and IRS-2, respectively (Lavan et al., 1997) . In addition, IRS-4 mRNA expression was markedly increased when L6 rat myoblast cells or P19 pluripotent embryonal carcinoma cells differentiated into myotubes, whereas expression of the other IRS members did not change (Giovannone et al., 2000) . This indicates that IRS-4 may regulate unique signaling pathways involved in cell growth and differentiation.
In quiescent and unstimulated cells, Brk and IRS-4 interact mainly through the Brk SH3 domain. Upon IGF-1 stimulation, we observed an increased interaction between Brk and IRS-4, presumably through increased Brk SH2 binding (Figure 2a ). This interaction increased the tyrosine phosphorylation and enzymatic activity of Brk (Figures 4b and 5 ). There are two potential mechanisms for this interaction-specific activation of Brk: release of autoinhibition and subcellular translocation. Brk activity is negatively regulated by intramolecular interactions involving SH3 and SH2 domains (Qiu and Miller, 2002) . The Brk SH3 domain interacts with the proline-rich region in the linker between SH2 and kinase domain, while the Brk SH2 domain appears to interact with Y447 in the C-terminus. Binding of IRS-4 to the Brk SH3 and SH2 domains would be expected to release these two domains from their intramolecular interactions and activate Brk, resulting in increased Brk phosphorylation.
The subcellular localization of Brk is variable in different cell types and under different conditions, but it includes both nuclear and cytoplasmic components. Brk has a short unique domain and lacks an N-terminal myristoylation site, suggesting that Brk would not be localized to the plasma membrane. Its interaction with membrane-localized IRS-4 could potentially bring Brk closer to the activated IGF1R or other transactivated tyrosine kinase receptors such as EGFR. Brk was reported to be phosphorylated by EGF stimulation and to interact with EGFR (Kamalati et al., 1996) . The relocalization of Brk from nucleus to cytoplasm has previously been shown to correlate with the progression of prostate tumorigenesis (Derry et al., 2003) . In that study, the kinase activity of Brk was reported to decrease upon cytoplasmic localization, and phosphorylation of the Brk substrate Sam68 decreased. We did not detect any change in phosphorylation of Sam68 in our system after IGF-1 stimulation (data not shown). The mechanism of Brk activation studied here would be unique, with Brk being recruited to plasma-membrane localized IRS-4 upon IGF-1 stimulation, with concomitant activation of Brk. Cytoplasmic Brk would presumably signal through substrates other than Sam68. It will be important to identify additional Brk substrates to explore the effects of this Brk activation.
One possible substrate for activated Brk would be IRS-4 itself. We found that overexpression of Brk did not affect the basal or IGF-1-induced phosphorylation of IRS-4 (Figure 3 ), arguing against this possibility. Moreover, Brk did not significantly affect the ability of IRS-4 to engage in complex formation with known signaling partners such as PI3K and Grb2, either in 293 or MCF-7 cells (Figures 3 and 4) . Consistent with these results, we did not detect significant changes in Erk1/2 or Akt phosphorylation when Brk was co-expressed with IRS-4 in MCF-7 cells (data not shown).
IRS proteins play important roles in both proliferation and differentiation induced by IR and IGF1R. The four IRS proteins have some redundant functions, as well as some unique roles that are still being clarified. IRS-4 knockout mice showed almost no phenotype, with slightly reduced weight and slightly lower glucose levels (Fantin et al., 2000) . IRS-4 was shown to play a compensatory role for IRS-1 in liver regeneration and brown adipocyte differentiation, and for IRS-2 in pancreatic beta-cells in antiapoptotic function (Escribano et al., 2003; Lingohr et al., 2003; Tseng et al., 2004) . There is evidence that IRS-4 has unique roles under some situations. IRS-4 mediates insulin-induced PKB signaling in 32D cells by mechanisms that differ from other IRS proteins (Uchida et al., 2000) . In mouse fibroblasts, IRS-4 was shown to increase cell proliferation in response to IGF-1 (Qu et al., 1999) . Aberrant IRS-4 expression can lead to abnormal growth in some cells. IRS-4 mRNA was detected in several carcinoma cells, including u-2 OS osteogenic sarcoma, Hep-2 larynx carcinoma, and A-431 epidermoid carcinoma cells (Giovannone et al., 2000) . We showed here that IRS-4 and Brk are co-expressed in two cell lines, A431 epidermoid carcinoma cells and MDA-MB-231 breast cancer cells (Figure 6 ). Co-immunoprecipitation experiments from A431 cells showed that there is an interaction between these two endogenously expressed proteins (Figure 7) , and that the interaction increases upon IGF-1 stimulation. In A431 cells, EGF stimulation has recently been shown to activate Brk, leading to paxillin phosphorylation, Rac activation, and increased cell motility (Chen et al., 2004) . Thus, the association between the two proteins, and subsequent Brk activation, could play a role in the increased proliferation and migration of these cells in response to IGF-1.
Materials and methods

Constructs and antibodies
Mammalian expression constructs for FLAG-tagged Brk, untagged Brk, and Brk mutants were described previously (Qiu and Miller, 2004) . The IRS-4 mammalian expression plasmid was a generous gift from Dr Derek LeRoith (NIH). Antibodies to Brk and IRS-4 were from Santa Cruz. Anti-phosphotyrosine antibody 4G10, anti-PI3K p85, and anti-Grb2 were purchased from Upstate Biotechnology.
FLAG-tagged Brk expression and pulldown
HEK 293 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 100 U/ml streptomycin sulfate, and 100 mg/ml amphotericin B. Cells were plated 24 h before transfection. FLAG-Brk expression plasmid was introduced using MIRUS TransIT (Mirus Corp.) according to the instructions from the manufacturer. After 48 h, the cells were washed twice with ice-cold phosphate-buffered saline and lysed in lysis buffer (20 mM Tris, pH 7.4, 1 mM EDTA, 1% Triton X-100, 140 mM NaCl, 2 mM vanadate, 5 mg/l aprotinin, 5 mg/l leupeptin, 0.1 mM phenylmethylsulfonyl fluoride) at 41C for 30 min. The cell lysates were centrifuged at 14 000 g for 15 min at 41C. Protein concentrations were determined using Bio-Rad protein assay. Lysates from untransfected and transfected 293 cells (75 mg protein in 25 ml volumes) were incubated with 100 ml anti-FLAG M2 affinity gel (Sigma) for 2 h at 41C. The beads were then washed twice with lysis buffer and three times with washing buffer (lysis buffer without Triton X-100). Bound proteins were eluted with 50 ml SDS-PAGE sample buffer (without DTT).
Identification of Brk-associated proteins
Proteins that eluted from the FLAG-BRK antibody were separated by one-dimensional SDS-PAGE and visualized by colloidal Coomassie blue staining. The entire lane was cut into 10 sections omitting the gel region containing the highly expressed Brk band. Gel bands were digested with trypsin as described previously (Joyal et al., 1997) . One-third of each unfractionated tryptic digest was analysed by on-line LC-ES MS/MS using a micro-column (Zorbax C18, 75 mm Â 15 cm, 3.5 mm particles) reverse-phase HPLC interfaced to an Agilent LC-MSD ion trap MS. ES MS/MS-based sequencing was performed on-line in a data-dependent manner (two tandem mass spectra per survey scan) (McCormack et al., 1997) as peptides eluted from the HPLC. Uninterpreted mass spectra from each of the 10 LC-MS/MS run were combined and searched as a single file for protein matches against a human nonredundant protein database using the program Mascot (Perkins et al., 1999) . The same protocol was used to analyse proteins eluting from the control experiment (untransfected cells).
GST purification and pulldown
GST, GST-Brk SH3, and GST-Brk SH2 were expressed in Escherichia coli NB42 cells. After IPTG induction, cells were harvested and lysed in a French pressure cell in GST lysis buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 100 mM EDTA, 1% Triton X-100, 10% glycerol, 5 mg/l aprotinin, 5 mg/l leupeptin, 0.1 mM phenylmethylsufonyl fluoride). Cell lysates were centrifuged at 14 000 g for 20 min. Supernatants were incubated with glutathione-agarose beads (Molecular Probes) for 1 h at 41C. The beads were then washed five times with 50 mM HEPES, pH 7.4, 100 mM EDTA. Glutathione-agarose with the same amount of immobilized GST, GST-BrkSH3, or GST-BrkSH2 was incubated with cell lysates from unstimulated or stimulated (4 nM IGF-1 for 10 min) 293 cells. After a 3-h incubation, the beads were washed for three times with lysis buffer, then boiled in SDS-PAGE sample buffer for 5 min. The eluted proteins were analysed by 10% SDS-PAGE.
Protein expression and immunoprecipitation
MCF-7, A431, and MDA-MB-231 cells were maintained in the same way as HEK 293 cells. Untagged Brk and IRS-4 plasmids were transfected and expressed as described above for FLAGtagged Brk. Cells were starved overnight before IGF-1 stimulation. After IGF-1 stimulation, cells were lysed in lysis buffer and centrifuged. Cell lysates (1 mg for MCF-7 and HEK 293 cells, or 2 mg for A431 and MDA-MB-231 cells) in 1 ml volumes were used for anti-Brk or anti-IRS-4 immunoprecipitation reactions. Lysates were mixed with 10 ml protein A beads (Sigma) at 41C for 3 h. The beads were then washed three times with lysis buffer and boiled for 5 min in SDS-PAGE sample buffer. The proteins were analyzed by 10% SDS-PAGE and transferred to PVDF membranes. Various primary antibodies and peroxidase-conjugated secondary antibodies were used. The immunoreactive proteins were visualized using an enhanced chemiluminescence (ECL) kit (Amersham Biosciences).
Immunoprecipitation/kinase assay MCF-7 cells were transfected with Brk alone, or with Brk plus IRS-4. Cells were left untreated or were stimulated with 4 nM IGF-1 for 10 min. After cell lysis at 41C for 30 min, immunoprecipitation reactions (1 ml volume) were carried out using anti-Brk antibody (1 mg) plus 1 mg cell lysate. After incubation at 41C for 30 min, protein A beads (10 ml) were added and the reaction proceeded for an additional 1 h. The beads were washed twice with lysis buffer, then twice with kinase buffer (50 mM Tris, pH 7.4, 10 mM MgCl 2 , 10mM MnCl 2 ). The kinase assay was carried out by addition of 25 ml of the assay buffer (50 mM Tris, pH 7.4, 10 mM MgCl 2 , 10 mM MnCl 2 , 0.1% b-ME, 200 mM ATP, 2 mCi 32 P-ATP). After 20 min at 301C, the assay was stopped by addition of SDSloading buffer and boiling. The reactions were analysed by 10% SDS-PAGE and autoradiography.
